美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

243.91

+1.840.76%

成交量：18.27万

成交额：4,444.80万

市值：289.40亿

市盈率：-65.86

高：246.51

开：244.10

低：240.30

收：242.07

数据加载中...

总览公司新闻公告

新事丨五家CXO公司，被剔除出创新药指数

中金公司研报指出百济神州日前展示了独特的研发战略、领先的血液瘤布局、以及广泛的实体瘤管线。在未来3-6 年公司计划继续在

武田中国前总裁单国洪将于8月18日加入百济神州出任大中华区、中亚和南亚区域总经理并向百济神州总裁、首席运营官吴晓滨汇报。

单国洪即将加入百济神州向吴晓滨汇报

南方财经网

百济神州6月30日成交额为9745.38万美元

【中金：维持百济神州(06160.HK)“跑赢行业”评级目标价198港元】智通财经APP获悉，中金发布研报称，维持百济

中金：维持百济神州(06160)“跑赢行业”评级目标价198港元

中国创新药5个月对外授权455亿美元，百济神州泽布替尼全球销售13亿美元！

中国创新药能否持续让世界买单？券商分析师最新观点

百济神州：开创性肿瘤平台行业标准制定者

中国国际金融股...

8家药企去年人均薪酬超过50万，包括百济神州、迪哲医药等

【交银国际：百济神州(06160.HK)新技术平台驱动目标价208.8港元维持“买入”评级】智通财经APP获悉，交银

百济神州的“创新超级乘法”

Ofweek维科网

BGB-43395：在既往三线治疗的乳腺癌及实体瘤患者具初步疗效和良好安全性

百济神州的新时代

百济神州6月27日成交额为9694.06万美元

百济神州研发日：未来 18 个月，预计将迎来 20 项里程碑进展

Insight数据库

百济神州的医保猜想：领先外企一个身位，还有必要谈吗？

叮当健康旗下药房上架百济神州注射用泽尼达妥单抗(百赫安)

港股收盘恒生指数跌0.17%恒生科技指数跌0.07%。港股科技ETF（159751）收盘上涨0.58%恒生港股通ETF（

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/ONC/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":243.91,"timestamp":1751394821779,"preClose":242.07,"halted":0,"volume":182668,"delay":0,"floatShares":75541600,"shares":118650020,"eps":-3.70325,"marketStatus":"交易中","change":1.84,"latestTime":"07-01 14:33:58 EDT","open":244.1,"high":246.51,"low":240.3,"amount":44447957.79528,"amplitude":0.025654,"askPrice":244.04,"askSize":10,"bidPrice":243.79,"bidSize":172,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1751400000000},"marketStatusCode":2,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":242.07,"preHourTrading":{"tag":"盘前","latestPrice":244.88,"preClose":242.07,"latestTime":"09:25 EDT","volume":1179,"amount":286875.29394,"timestamp":1751376333341},"postHourTrading":{"tag":"盘后","latestPrice":242.07,"preClose":242.07,"latestTime":"19:22 EDT","volume":8730,"amount":2113264.85,"timestamp":1751325724133},"volumeRatio":0.597419,"impliedVol":0.4515,"impliedVolPercentile":0.6911},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.597439,"shares":118650020,"dividePrice":0,"high":246.51,"amplitude":0.025654,"preClose":242.07,"low":240.3,"week52Low":142,"pbRate":"8.27","psRate":"6.93","week52High":287.88,"institutionHeld":0,"latestPrice":243.91,"committee":0.889503,"eps":-3.70325,"divideRate":0,"volume":182674,"delay":0,"ttmEps":-3.70325,"open":244.1,"prevYearClose":184.71,"prevWeekClose":241.2,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":266.8,"twentyDayClose":245.93,"sixtyDayClose":264.32},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548000672","title":"新事丨五家CXO公司，被剔除出创新药指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2548000672","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548000672?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 22:28","pubTimestamp":1751380123,"startTime":"0","endTime":"0","summary":"6月30日，恒生港股通创新药指数宣布修订编制方案，明确剔除CXO公司，聚焦创新药核心公司。根据新的编制方案，药明生物、药明康德、金斯瑞、药明合联、晶泰控股5家公司，将从恒生港股通创新药指数中剔除。截至6月30日，恒生港股通创新药精选指数上半年涨幅达到58.95%。修订后，恒生港股通创新药指数前五大成分股，分别是信达生物、百济神州、康方生物、石药集团、中国生物制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701223315a4c9336d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701223315a4c9336d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02228","BK4139","CXO","ONC","BK4526"],"gpt_icon":0},{"id":"2548207832","title":"中金公司研报指出百济神州日前展示了独特的研发战略、领先的血液瘤布局、以及广泛的实体瘤管线。在未来3-6 年公司计划继续在","url":"https://stock-news.laohu8.com/highlight/detail?id=2548207832","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548207832?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 15:31","pubTimestamp":1751355081,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4230","LU0307460666.USD","LU2328871848.SGD","ONC","CAR","BK1583","LU1969619763.USD","688235","DCF","BK1588","BK4526","BK0239","BK1500","BK4139","BK1161","06160","BK4022","LU0588546209.SGD"],"gpt_icon":0},{"id":"2548022510","title":"武田中国前总裁单国洪将于8月18日加入百济神州出任大中华区、中亚和南亚区域总经理并向百济神州总裁、首席运营官吴晓滨汇报。","url":"https://stock-news.laohu8.com/highlight/detail?id=2548022510","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548022510?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 14:21","pubTimestamp":1751350882,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02197","BK1583","LU0307460666.USD","06160","ONC","LU0588546209.SGD","BK1161","BK0239","BK1588","BK4526","LU1969619763.USD","688235","LU2328871848.SGD","BK1500","BK4139"],"gpt_icon":0},{"id":"2548022919","title":"单国洪即将加入百济神州 向吴晓滨汇报","url":"https://stock-news.laohu8.com/highlight/detail?id=2548022919","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548022919?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 14:13","pubTimestamp":1751350433,"startTime":"0","endTime":"0","summary":"南方财经7月1日电，原武田制药全球高级副总裁、武田中国总裁单国洪(SeanShan)将于2025年8月18日加入百济神州，出任大中华区、中亚和南亚区域总经理，并向吴晓滨汇报。单国洪将主导百济神州在大中华区、中亚和南亚这一关键增长区域的运营与战略发展，同时还将推进构建高效协同的区域运营模式，最大程度响应患者需求，助力公司全球化战略的深入实施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507013445012475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","LU0307460666.USD","06160","BK1588","BK4526","BK1161","LU0588546209.SGD","ONC","LU2328871848.SGD","BK1500","LU1969619763.USD","BK1583","02197"],"gpt_icon":0},{"id":"2548026060","title":"百济神州6月30日成交额为9745.38万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548026060","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548026060?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 12:14","pubTimestamp":1751343249,"startTime":"0","endTime":"0","summary":"美东时间2025年6月30日，百济神州成交额为9745.38万美元，成交额较昨日增加0.53%，当日成交量为40.21万股。百济神州于2025年6月30日涨0.36%，报242.07美元，该股过去5个交易日跌6.0%，年初至今涨31.05%，过去60日跌11.9%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701121416a4c80ca2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701121416a4c80ca2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526"],"gpt_icon":0},{"id":"2548223042","title":"【中金：维持百济神州(06160.HK)“跑赢行业”评级 目标价198港元】智通财经APP获悉，中金发布研报称，维持百济","url":"https://stock-news.laohu8.com/highlight/detail?id=2548223042","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548223042?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 09:19","pubTimestamp":1751332770,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ONC","BK1500","BK1588","LU1969619763.USD","BK4526","06160","BK4139","LU0588546209.SGD","BK1583","LU2328871848.SGD","BK1161","688235","DCF","LU0307460666.USD","BK0239"],"gpt_icon":0},{"id":"2548042228","title":"中金：维持百济神州(06160)“跑赢行业”评级 目标价198港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548042228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548042228?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 09:19","pubTimestamp":1751332770,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持百济神州2025年和2026年盈利预测不变。该行维持跑赢行业评级，基于DCF模型，该行维持A/H/US股目标价280元/198港元/332美元。6月26日，公司在投资者研发日活动中，展示了独特的研发战略、领先的血液瘤布局、以及广泛的实体瘤管线。公司继续沿用了百悦泽的成功开发经验，多管线并行创新，唯优质分子推向临床，这也是这些新分子在临床前就展示了BIC潜力的原因之一。另外IRAK4 CDAC半衰期优秀，计划于2H25启动II期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1312457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688235","ONC","06160"],"gpt_icon":0},{"id":"2548104668","title":"中国创新药5个月对外授权455亿美元，百济神州泽布替尼全球销售13亿美元！","url":"https://stock-news.laohu8.com/highlight/detail?id=2548104668","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548104668?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 06:53","pubTimestamp":1751324002,"startTime":"0","endTime":"0","summary":"2025年前五个月，国内创新药企对外授权交易总金额已达455亿美元，超越2024年上半年交易总额。百济神州缔造了中国药企首个十亿美元重磅药泽布替尼，该药于2019年在美国FDA首次获批上市，2023年全球销售额达13亿美元。2024年百济神州实现收入38亿美元，核心产品泽布替尼贡献收入26亿美元，推动公司亏损额持续收窄。这一突破标志着中国创新药在全球医药创新格局中地位的提升。商业化成果显著中国创新药企业对外授权交易金额屡创新高。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/01065351396453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1588","LU1969619763.USD","BK0239","BK1161","LU0307460666.USD","LU2328871848.SGD","ONC","BK4139","BK1583","06978","159992","688235","LU0588546209.SGD","BK1574","BK1500","06160","BK4526"],"gpt_icon":0},{"id":"2547015164","title":"中国创新药能否持续让世界买单？券商分析师最新观点","url":"https://stock-news.laohu8.com/highlight/detail?id=2547015164","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547015164?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 23:29","pubTimestamp":1751297340,"startTime":"0","endTime":"0","summary":"医药魔方统计，2025年1—5月，中国创新药企对外授权交易总金额已达455亿美元，超过2024年上半年的交易总额，创新药出海授权交易大爆发。亮眼数据的背后，是中国创新药整体水平的强势崛起。“中国创新药产业的研发、临床与生产能力，正处于与国际一线水平接轨的初始阶段。”由于BD数据不及预期，年内大涨明显的创新药企业荣昌生物股价近期大幅回调，从而带动创新药板块整体调整。华泰柏瑞恒生创新药ETF6月中旬以来一度单周下行超过8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688181","600557","600535","600645","600998","06160","600200","600682","603127","688068","600867","688336","600513","603229","603259","600062","600572","600332","600380","603456","688073","600276","BK0239","603367","688136","688131","688222","688198","688177","603590","688166","688321","600216","600881","601089","688505","688317","ONC","600196","603998","688278","688202","688091","600267","603707","688235","688331","600789","688520","600721","688513","600851","688163","600351","688488","600080","159992","600222","688506","601607","600521","688117","600056","603087","605199","688356","600079","603716","603567","688189","688319","600420","600774","600422"],"gpt_icon":0},{"id":"2547096481","title":"百济神州：开创性肿瘤平台 行业标准制定者","url":"https://stock-news.laohu8.com/highlight/detail?id=2547096481","media":"中国国际金融股...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547096481?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 19:48","pubTimestamp":1751284087,"startTime":"0","endTime":"0","summary":"公司近况6 月26 日，公司在投资者研发日活动中，展示了独特的研发战略、领先的血液瘤布局、以及广泛的实体瘤管线。公司继续沿用了百悦泽的成功开发经验，多管线并行创新，唯优质分子推向临床，这也是这些新分子在临床前就展示了BIC潜力的原因之一。另外IRAK4 CDAC半衰期优秀，计划于2H25 启动II期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063019481197948d97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063019481197948d97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","BK4139","ONC","BK4526"],"gpt_icon":0},{"id":"2547531310","title":"8家药企去年人均薪酬超过50万，包括百济神州、迪哲医药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2547531310","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547531310?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 12:07","pubTimestamp":1751256420,"startTime":"0","endTime":"0","summary":"根据2024年财报，8家药企人均薪酬超过50万元，其中百济神州以90.48万元位居榜首，员工人数达1.1万人。百济神州不仅在血液学领域有显著进展，还在实体瘤领域拓展了多元管线。迪哲医药人均薪酬68.67万元，其两款产品舒沃替尼和戈利昔替尼已在中国获批上市，并带动公司营收大幅增长。亚虹医药、益方生物、盟科药业、艾力斯、福瑞股份、诺诚健华的人均薪酬分别为62.74万元、61.91万元、56.4万元、55.36万元、53.66万元、52.82万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063012131297941cff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063012131297941cff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","ONC","688235","BK4526","BK4139"],"gpt_icon":0},{"id":"2547303680","title":"【交银国际：百济神州(06160.HK)新技术平台驱动 目标价208.8港元 维持“买入”评级】智通财经APP获悉，交银","url":"https://stock-news.laohu8.com/highlight/detail?id=2547303680","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547303680?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 10:42","pubTimestamp":1751251379,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ONC","BK1500","BK1588","LU1969619763.USD","BK4526","06160","BK4139","BK4231","BK1583","LU0588546209.SGD","BK4080","LU2328871848.SGD","ADC","BK1161","688235","LU0307460666.USD","BK0239"],"gpt_icon":0},{"id":"2547740039","title":"百济神州的“创新超级乘法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2547740039","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547740039?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 09:27","pubTimestamp":1751246828,"startTime":"0","endTime":"0","summary":"百济神州的研发效率极高。着眼未来，百济神州仍计划保持这种快速验证的势头。这种管线的广度、深度及推进速度，无疑是其“创新超级乘法”最直观的体现。巩固血液瘤基本盘的同时，百济神州进军高发实体瘤领域，布局多样化且差异化的新分子。“专注”之外，百济神州提升确定性的另一关键策略是积极拓展“联合疗法”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506300928009793f2a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506300928009793f2a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1500","LU0307460666.USD","BK1583","LU2328871848.SGD","06160","688235","BK1588","ONC","LU0588546209.SGD","LU1969619763.USD"],"gpt_icon":0},{"id":"2547005844","title":"BGB-43395：在既往三线治疗的乳腺癌及实体瘤患者具初步疗效和良好安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=2547005844","media":"山西证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547005844?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 00:00","pubTimestamp":1751212800,"startTime":"0","endTime":"0","summary":"BGB-43395 是CDK4 的高度选择性抑制剂，靶向控制细胞分裂的检查点蛋白以阻止癌细胞生长。BGB-43395具有潜在同类最佳血液学安全性特征，在既往接受过多线治疗的CDK4/6 经治患者中临床治疗有效。BGB-43395 剂量优化后安全性良好，血液毒性发生率低。BGB-43395 与氟维司群联用在实体瘤患者中观察到初步抗肿瘤活性。BGB-43395+氟维司群剂量递增给药后，37 例可评价实体瘤患者的ORR 为15%，其中19 例可评价乳腺癌患者的ORR 为11%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630115118a72524a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630115118a72524a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688235","ONC","06160"],"gpt_icon":0},{"id":"2547085826","title":"百济神州的新时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2547085826","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547085826?lang=zh_cn&edition=fundamental","pubTime":"2025-06-29 16:37","pubTimestamp":1751186273,"startTime":"0","endTime":"0","summary":"继首季度盈利之后，近日举办的投资者研发日活动让百济神州又一次站在聚光灯下。泽布替尼只是开始，百济神州血液瘤的上市产品格局即将焕新，新王牌索托克拉已在华申报上市，并预计在今年下半年推进全球申报。基于此，百济神州将在今年Q3开放乳腺癌和妇科恶性肿瘤的肿瘤特异性扩展队列，以进一步确认BG-C9074在B7-H4高表达肿瘤患者中的疗效和安全性。在肺癌领域，百济神州正在打造行业领先的产品组合。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250629164711a723c846&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250629164711a723c846&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","LU0307460666.USD","BK1500","06160","LU1969619763.USD","BK1583","BK1161","688235","LU0588546209.SGD","LU2328871848.SGD","ONC"],"gpt_icon":0},{"id":"2546763867","title":"百济神州6月27日成交额为9694.06万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546763867","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546763867?lang=zh_cn&edition=fundamental","pubTime":"2025-06-28 12:18","pubTimestamp":1751084322,"startTime":"0","endTime":"0","summary":"美东时间2025年6月27日，百济神州成交额为9694.06万美元，成交额较昨日减少9.17%，当日成交量为40.08万股。百济神州于2025年6月27日跌5.22%，报241.2美元，该股过去5个交易日跌2.38%，年初至今涨30.58%，过去60日跌11.01%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628121843a7220f4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628121843a7220f4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2546772031","title":"百济神州研发日：未来 18 个月，预计将迎来 20 项里程碑进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2546772031","media":"Insight数据库","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546772031?lang=zh_cn&edition=fundamental","pubTime":"2025-06-28 08:04","pubTimestamp":1751069069,"startTime":"0","endTime":"0","summary":"6 月 26 日，百济神州举行了投资者研发日活动。未来 18 个月内，预计将迎来 20 项里程碑进展。百济神州现拥有 1200+名科研人员，覆盖多样化的治疗模式。截至 5 月 28 日，百济正在进行临床开发的产品有 30 个，进行中的临床试验有 96 项。百济神州是唯一一家在 3 个 CLL 基础作用机制中均拥有潜在 BIC 产品的公司。预期里程碑事件展望未来 18 个月，百济神州将有望迎来多个关键后期催化剂和关键早期催化剂事件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628081518a721bdba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628081518a721bdba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","BK0239","688235"],"gpt_icon":0},{"id":"2546774624","title":"百济神州的医保猜想：领先外企一个身位，还有必要谈吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2546774624","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546774624?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 20:46","pubTimestamp":1751028396,"startTime":"0","endTime":"0","summary":"5月29日，百济神州HER2靶点的重磅新药泽尼达妥单抗正式获批上市，用于治疗既往接受过全身治疗的HER2高表达不可切除局部晚期或转移性胆道癌患者。泽尼达妥单抗成为全球首个且目前唯一获批用于靶向治疗HER2高表达胆道癌的产品，领先一个身位。据百济神州官方最新消息，首批泽尼达妥单抗已经在全国百余个城市的医院和药房落地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627210128a4c14cea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627210128a4c14cea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688235","BK4526","BK4139","06160"],"gpt_icon":0},{"id":"2546671877","title":"叮当健康旗下药房上架百济神州注射用泽尼达妥单抗(百赫安)","url":"https://stock-news.laohu8.com/highlight/detail?id=2546671877","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546671877?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 16:48","pubTimestamp":1751014120,"startTime":"0","endTime":"0","summary":"日前, 百济神州双特异性HER2抑制剂百赫安首批药物在叮当健康旗下药房等渠道上架发售,6 月24日,于叮当健康旗下药房正式售出首单。注射用泽尼达妥单抗于2025年5月29日,获附条件批准,用于既往接受过治疗的患者。据了解,叮当健康于2025年持续推进新特药‘生命方舟计划’,在旗下药房全面加强新特药品类布局,已先后上架阿尔茨海默病药品记能达、1类新药注射用瑞康曲妥珠单抗(艾维达)等新特药产品,为提升患者用药可及性带来便利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627165221952ddb11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627165221952ddb11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","09886","06160","BK0239","688235"],"gpt_icon":0},{"id":"2546792746","title":"港股收盘恒生指数跌0.17%恒生科技指数跌0.07%。港股科技ETF（159751）收盘上涨0.58%恒生港股通ETF（","url":"https://stock-news.laohu8.com/highlight/detail?id=2546792746","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546792746?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 16:09","pubTimestamp":1751011791,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0823413660.USD","513600","HSTECH","HSI","XIACY","LU0708995583.HKD","LU0143863784.USD","LU0164865239.USD","513990","MIUmain","LU1981816686.USD","BK1523","06160","HSCEI","688235","LU2097828474.EUR","159751","LU0823039010.USD","LU0235996351.USD","BK1588","LU2226246903.HKD","BK1502","HHImain","ONC","LU2097828805.USD","01810","SG9999002463.SGD","159318","LU1303224171.USD","LU1880383440.USD","BK1500","LU2257852520.SGD","LU0823426480.USD","LU0348814723.USD","LU0540923850.HKD","YANG","LU0700851271.USD","513020","LU0211977185.USD","LU0327786744.USD","LU0052750758.USD","LU0823426308.USD","MCHmain","07226","02833","81810","HSImain","BK1193","HXXD.SI","MHImain"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盘前","dateTimestamp":1756526400000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盘前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748491200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-06-30","current":-72.937983,"percent":0.073529,"low":-89.808695,"twenty":-44.955897,"median":-38.680521,"eighty":-23.08713,"high":-19.234246,"avg":-38.500754,"sd":16.940238,"marketCap":28618384824},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-06-30","current":-72.937983,"twenty":-44.955897,"median":-38.680521,"eighty":-23.08713,"marketCap":28618384824}],"updateTime":1751394838997}}}